<DOC>
	<DOCNO>NCT00528424</DOCNO>
	<brief_summary>Study AUX-CC-858 open-label continuation double-blind Study AUX-CC-857 ( NCT00528606 ) . Subjects complete Day 90 visit initial injection Study AUX-CC-857 ( NCT00528606 ) enter Study AUX-CC-858 . Subjects require treatment Study AUX-CC-858 , either treat metacarpophalangeal and/or proximal interphalangeal ( PIP ) joint reduction contracture 5° less , cord affect joint receive less three injection AA4500 , eligible cord receive treatment AUX-CC-857 ( NCT00528606 ) , option receive five injection AA4500 extension study . Subjects require treatment follow efficacy safety Days 1 , 7 , 30 injection , injection separate four week . Follow-up visit determination efficacy safety conduct Day 90 , Month 6 , Month 9 . This study design part large clinical program , adult patient Dupuytren 's contracture palpable cord , data 2 pivotal Placebo-Controlled study ( AUX-CC-857 ( NCT00528606 ) AUX-CC-859 ( NCT00533273 ) ) 7 non-pivotal study evaluate .</brief_summary>
	<brief_title>AA4500 ( XIAFLEX™ , Proposed Name ) Treatment Advanced Dupuytren 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Dupuytren Contracture</mesh_term>
	<criteria>Subjects diagnosis advance Dupuytren 's disease , fix flexion deformity least one finger , thumb , contracture least 20° , great 100° MP ( 80° PIP ) joint , cause palpable cord . Had positive `` table top test , '' define inability simultaneously place affect finger ( ) palm flat table top . Were naïve AA4500 treatment receive one two injection AA4500 treatment advance Dupuytren 's disease AUXCC857 ( ( NCT00528606 ) . Were judge good health . Must participate protocol AUXCC857 ( NCT00528606 ) . Had chronic muscular , neurological , neuromuscular disorder affect hand . Had receive treatment advance Dupuytren 's disease within 90 day enrollment joint select initial injection AA4500 , include surgery ( fasciectomy surgical fasciotomy ) , needle aponeurotomy/fasciotomy , injection verapamil and/or interferon . Had know recent history stroke , bleeding , disease process affect hand , medical condition , investigator 's opinion , would make subject unsuitable enrollment study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>